Since the Supreme Court unanimously tossed the anti-abortion challenge to mifepristone on standing grounds earlier this week, one thing has become clear: the ruling settled nothing about the drug's legality.

The Court did NOT rule that mifepristone is safe. It did NOT rule that the FDA approval process was sound. It ruled that the specific plaintiffs — a coalition of anti-abortion doctors organized under the Alliance for Hippocratic Medicine — could not demonstrate they were actually harmed by the drug's availability. That is a procedural off-ramp, not a constitutional verdict.

What the Coverage Is Getting Wrong

Most mainstream coverage this week framed the ruling as a decisive win for abortion access. That framing is incomplete at best and misleading at worst.

The Court's unanimous decision — written by Justice Brett Kavanaugh — explicitly left open the question of whether a future plaintiff with proper standing could bring the same challenge and win. Kavanaugh noted that anti-abortion states, not just private doctors, may have a cleaner path to standing. Anti-abortion legal strategists are reading this carefully.

Several Republican state attorneys general have already signaled they are reviewing exactly that path. The legal infrastructure to re-litigate mifepristone access is not being dismantled. It is being rebuilt.

The State-Level Picture

While the federal case was dismissed, 21 states have enacted their own restrictions on medication abortion — including mifepristone specifically — that remain fully in effect. According to the Guttmacher Institute, roughly 40% of U.S. women of reproductive age live in states where abortion access is significantly restricted or banned outright.

Mifepristone can be federally approved and still practically unavailable to millions of Americans. The national media's focus on the Supreme Court ruling has largely obscured this reality.

The FDA Approval Question Is Not Dead

The original lawsuit challenged the FDA's 2000 approval of mifepristone and its subsequent 2016 and 2021 regulatory updates that expanded access — including allowing it to be dispensed by mail. The Fifth Circuit Court of Appeals had partially sided with the challengers on the merits before the Supreme Court intervened on standing.

That Fifth Circuit reasoning did not vanish. A new plaintiff with better-established standing could walk right back into the Fifth Circuit — which covers Texas, Louisiana, and Mississippi — with essentially the same substantive arguments and potentially get a different outcome at the district level.

Judge Matthew Kacsmaryk in Amarillo, Texas, the district judge who initially ruled AGAINST mifepristone access in 2023, is still on the bench. He is still in the Fifth Circuit's jurisdiction. Anti-abortion legal groups know this.

What the Right Should Be Saying — But Largely Isn't

Conservative media has been oddly muted on the strategic implications here. The ruling is being treated as a loss when it is actually a delay. Organizations like the Alliance Defending Freedom and Americans United for Life have not publicly declared defeat — because they haven't lost on the merits. They lost on a technicality about who can sue.

That is a solvable problem for them. Expect a new case with state-level plaintiffs within 12 to 18 months.

What the Left Should Be Saying — But Isn't

Pro-abortion-access advocates are celebrating a ruling that, by design, punted the hard question. The celebration is understandable. It is also premature.

The FDA's regulatory authority over mifepristone remains vulnerable. If a future administration — Republican or Democrat — instructed the FDA to revisit its approval standards, the agency could do so. The Supreme Court ruling this week offers ZERO protection against that scenario. ZERO.

Additionally, the mail-order distribution rules that dramatically expanded access in 2021 remain a live target. Pharmacy dispensing requirements, telemedicine prescribing rules, and cross-state mailing restrictions are all still being contested in multiple venues.

What This Means for Access

If you live in a state where abortion is legal and mifepristone is accessible, this week's ruling changes nothing for you — access was not being actively blocked at the federal level.

If you live in a state with restrictions, this ruling also changes nothing for you — those restrictions are still in place.

The Supreme Court handed down a unanimous decision that was genuinely significant as a legal matter and genuinely limited as a practical matter. The coverage treating it as a final resolution is doing readers a disservice.